Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Skin Neoplasms 1Recurrence 1Neoplasms 1Multiple Sclerosis, Relapsing-Remitting 1Multiple Sclerosis 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Leukemia, Lymphocytic, Chronic, B-Cell 1Gliosarcoma 1Glioblastoma 1Carcinoma, Basal Cell 1

Interventions

Cyclophosphamide 155Dexamethasone 141Rituximab 85fludarabine 80Lenalidomide 72Cytarabine 70Bortezomib 65fludarabine phosphate 63Gemcitabine 62venetoclax 55pomalidomide 53Etoposide 53pembrolizumab 52Paclitaxel 48Cisplatin 48Carboplatin 48Peripheral Blood Stem Cell Transplantation 47Filgrastim 40Radiotherapy 39Busulfan 37Calcium Dobesilate 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 30Vincristine 29Bendamustine Hydrochloride 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Dimethyl Fumarate × Clear all
NCT02784834 2019-09-19

Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL

University of California, San Diego

Phase 1 Terminated
2 enrolled 5 charts
LymphoidOther hematologic neoplasm

Neoplasms, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡